June 30, 2026
ALIV offers two distinct metabolic support IV protocols — the Trim & Tone Elixir and FatLoss Max — and patients frequently ask which one is appropriate for their situation. The answer is clinical, not cosmetic: the right choice depends on your specific metabolic picture, deficiency profile, and treatment goals. Here is how our Pune and Mumbai clinical teams think about the decision.
The Trim & Tone Elixir is designed for patients who are in a broadly healthy metabolic range but want targeted nutritional support for body composition optimisation — patients who are already exercising consistently, managing their diet reasonably well, and want to address the specific micronutrient gaps that may be limiting their results. The formulation emphasises B vitamins (particularly B1, B2, B3, and B5 — all involved in energy metabolism and mitochondrial function), L-carnitine (which supports the transport of long-chain fatty acids into the mitochondria for oxidation, a genuine metabolic mechanism rather than marketing language), and magnesium (which supports insulin sensitivity and is commonly deficient in physically active urban adults). The Trim & Tone is the appropriate starting point for patients whose metabolism is not significantly dysfunctional but who want targeted clinical support for their body composition goals alongside their lifestyle programme.
FatLoss Max is designed for patients with more significant metabolic dysfunction — higher HOMA-IR, more established visceral fat accumulation, or the metabolic picture of patients with PCOS-related weight challenges, fatty liver, or prediabetes. The formulation is more intensive: it includes higher doses of the metabolic support nutrients in Trim & Tone, with additional components targeting insulin sensitivity and inflammatory markers directly. FatLoss Max is the appropriate protocol for patients who need more than micronutrient optimisation — they need clinical metabolic support as a component of a comprehensive programme. It is offered at ALIV alongside — not instead of — the dietary, exercise, and sleep changes that address the root causes of the metabolic dysfunction.
The decision between these two formulations is made at your ALIV clinical assessment based on: your HOMA-IR and fasting insulin; your waist circumference and abdominal fat distribution; whether PCOS, fatty liver, or prediabetes is present; your existing exercise programme and diet quality; and your response to any previous metabolic interventions. Neither formulation is a weight loss treatment in isolation. Both are clinical adjuncts to the foundational lifestyle work that produces meaningful and sustained metabolic change. Read our complete metabolic health guide: metabolic health in India.
Typically no — they are alternatives rather than complements. Starting with the more appropriate formulation and adjusting based on clinical response is the standard ALIV approach. The specific combination of nutrients is determined by your clinical picture, and combining both protocols without a specific clinical rationale adds unnecessary cost without proportional clinical benefit.
A standard initial course is six to eight sessions, typically weekly or bi-weekly, followed by a clinical review of response markers. Maintenance sessions vary based on the outcome of this review and the patient's ongoing dietary and lifestyle context. For patients with significant metabolic dysfunction on FatLoss Max, a longer initial course of eight to twelve sessions may be appropriate before reassessment.
We cannot and will not make specific weight loss predictions linked to either protocol. Body composition change is driven primarily by the foundational lifestyle factors — dietary quality, physical activity, sleep, and stress management. The IV protocols support the metabolic environment in which those changes produce results. Patients who are consistent with both the IV programme and the foundational lifestyle changes generally see meaningful improvements in metabolic markers within eight to twelve weeks, with body composition changes following on a longer timeline of three to six months.
Yes — and patients with PCOS are among those for whom FatLoss Max is most clinically appropriate. The formulation's insulin-sensitising components directly address PCOS's primary metabolic driver, and the absence of hormonal components means there is no concern about interference with the hormonal picture being managed pharmacologically. Disclose all current medications (including metformin, oral contraceptives, and hormonal treatments) at your ALIV assessment so formulation decisions can be made with full clinical context. Read: PCOS Balancer IV at ALIV.
Prescription weight loss medications (GLP-1 agonists, orlistat, etc.) act through specific pharmacological mechanisms that produce more potent and direct effects on appetite, caloric absorption, or metabolic rate. IV metabolic support at ALIV is not a medication and does not produce equivalent direct pharmacological effects. It is appropriate as a supportive clinical intervention for patients who do not meet criteria for or are not interested in prescription medications, or as a complement to a broader programme that may include medication where clinically indicated.